JP2015530387A - 脂質複合体化シスプラチンによる肺癌の再発防止 - Google Patents

脂質複合体化シスプラチンによる肺癌の再発防止 Download PDF

Info

Publication number
JP2015530387A
JP2015530387A JP2015530149A JP2015530149A JP2015530387A JP 2015530387 A JP2015530387 A JP 2015530387A JP 2015530149 A JP2015530149 A JP 2015530149A JP 2015530149 A JP2015530149 A JP 2015530149A JP 2015530387 A JP2015530387 A JP 2015530387A
Authority
JP
Japan
Prior art keywords
lung
bone
use according
osteosarcoma
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015530149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530387A5 (enExample
Inventor
フォレスト エイチ． アンソニー，
フォレスト エイチ． アンソニー，
マシュー エム． パリス，
マシュー エム． パリス，
エドウィン ジェイ． トーマス，
エドウィン ジェイ． トーマス，
グアンタオ ザン，
グアンタオ ザン，
Original Assignee
エライゾン ファーマシューティカルズ， エルエルシー
エライゾン ファーマシューティカルズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エライゾン ファーマシューティカルズ， エルエルシー, エライゾン ファーマシューティカルズ， エルエルシー filed Critical エライゾン ファーマシューティカルズ， エルエルシー
Publication of JP2015530387A publication Critical patent/JP2015530387A/ja
Publication of JP2015530387A5 publication Critical patent/JP2015530387A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015530149A 2012-09-04 2013-09-04 脂質複合体化シスプラチンによる肺癌の再発防止 Pending JP2015530387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261743398P 2012-09-04 2012-09-04
US61/743,398 2012-09-04
PCT/US2013/058025 WO2014039533A2 (en) 2012-09-04 2013-09-04 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Publications (2)

Publication Number Publication Date
JP2015530387A true JP2015530387A (ja) 2015-10-15
JP2015530387A5 JP2015530387A5 (enExample) 2016-10-20

Family

ID=50187920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015530149A Pending JP2015530387A (ja) 2012-09-04 2013-09-04 脂質複合体化シスプラチンによる肺癌の再発防止

Country Status (10)

Country Link
US (1) US11291644B2 (enExample)
EP (1) EP2892524B1 (enExample)
JP (1) JP2015530387A (enExample)
CN (3) CN112451486A (enExample)
CA (1) CA2883703C (enExample)
DK (1) DK2892524T3 (enExample)
ES (1) ES2848025T3 (enExample)
MX (1) MX2015002842A (enExample)
PL (1) PL2892524T3 (enExample)
WO (1) WO2014039533A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
EP3643320B1 (en) * 2013-07-08 2025-09-03 International Dehydrated Foods, Inc. Compositions prepared from poultry for use in the treatment of diabetes
EP3113799A1 (en) * 2014-03-07 2017-01-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
CN109568336B (zh) * 2018-12-29 2021-10-08 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
AU2022232631A1 (en) 2021-03-11 2023-09-21 KaloCyte, Inc. Compositions and methods for removing bio-synthetic nano-particles from bodily fluids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501006A (ja) * 2006-08-16 2010-01-14 トランセイブ， インク． 高い活性を有する白金化合物製剤の吸入による投与

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5435989A (en) 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4590001A (en) 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
USRE33071E (en) 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4572425A (en) 1983-08-01 1986-02-25 Russell William S Reusable container
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
ATE113468T1 (de) 1987-07-29 1994-11-15 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
IL83380A (en) 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
ATE77051T1 (de) 1988-03-04 1992-06-15 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US5141751A (en) 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0551169A1 (en) 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
CN1088777A (zh) 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
EP0896816A4 (en) 1996-02-26 2002-06-12 Daiichi Seiyaku Co LIPOSOME AND LIPOSOME DISPERSION
PT910382E (pt) 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998024424A1 (en) 1996-12-03 1998-06-11 Rijksuniversiteit Utrecht Cisplatinum comprising pharmaceutical
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
NZ336381A (en) 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
BR9815445A (pt) 1997-02-05 2001-09-25 Pharmacia & Upjohn Spa Complexos lipìdicos e lipossomas de complexos de platina altamente insolúveis
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
CN100358494C (zh) 1998-11-12 2008-01-02 弗兰克G·皮尔基威克兹 一种吸入给药系统
US20050074499A1 (en) 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
EP1206234A4 (en) 1999-06-03 2005-06-01 Jessie L S Au METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
WO2001032139A2 (en) 1999-11-05 2001-05-10 Seed Capital Investment-2 (Sci-2) B.V. Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
AU777338B2 (en) 1999-12-04 2004-10-14 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
ATE341310T1 (de) 2000-02-04 2006-10-15 Lipoxen Technologies Ltd Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
CA2402613A1 (en) 2000-03-29 2001-10-04 Igor Gonda Cationic liposomes
US20030124180A1 (en) 2000-05-02 2003-07-03 Jurgen Ebert Liposomes containing active substances
US6998393B2 (en) 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
AU7038501A (en) 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
WO2002060412A2 (en) 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
PT1320355E (pt) 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
EP1424898A4 (en) 2001-08-20 2008-04-02 Transave Inc TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM
US20030059375A1 (en) 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
EP1545459A4 (en) 2002-08-02 2007-08-22 Transave Inc PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
ES2439727T3 (es) 2002-10-29 2014-01-24 Insmed Incorporated Liberación sostenida de antiinfectantes
US20040156888A1 (en) 2002-11-26 2004-08-12 Jensen Gerard M. Liposomal formulations
WO2005070465A2 (en) 2004-01-14 2005-08-04 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
WO2005089448A2 (en) 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
AU2005245018A1 (en) 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2006055352A2 (en) 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
US20060159712A1 (en) 2004-12-14 2006-07-20 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
WO2006113181A2 (en) * 2005-04-08 2006-10-26 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190182A1 (en) 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20090130194A1 (en) * 2005-11-08 2009-05-21 Transave, Inc. Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
WO2007064658A2 (en) 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
GR20060100144A (el) 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
BRPI1010642A2 (pt) * 2009-05-14 2016-03-15 Oatmeal Biotechnologies Group L L C tecnologias de plataforma para doenças ocorrendo espontaneamente
CN107412749A (zh) 2010-02-22 2017-12-01 优势医疗公司 治疗脑的出血性病状的方法和组合物
JP2013541497A (ja) * 2010-07-16 2013-11-14 エペイウス バイオテクノロジーズ コーポレイション 癌および他の障害のための標的指向ナノ粒子
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501006A (ja) * 2006-08-16 2010-01-14 トランセイブ， インク． 高い活性を有する白金化合物製剤の吸入による投与

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol. 12, no. 7, JPN6017016357, 2011, pages 1717 - 1722, ISSN: 0003553792 *
CANCER RESEARCH, vol. 70, no. 11, JPN6017016356, 2010, pages 4602 - 4612, ISSN: 0003553791 *
肺癌, vol. 12, no. 1, JPN6017016355, 1972, pages 27 - 35, ISSN: 0003553790 *

Also Published As

Publication number Publication date
CN105025904A (zh) 2015-11-04
EP2892524A4 (en) 2016-07-06
CA2883703A1 (en) 2014-03-13
PL2892524T3 (pl) 2021-10-25
US11291644B2 (en) 2022-04-05
EP2892524A2 (en) 2015-07-15
WO2014039533A3 (en) 2015-07-16
EP2892524B1 (en) 2020-11-25
US20140065205A1 (en) 2014-03-06
DK2892524T3 (da) 2021-01-25
CN115414384A (zh) 2022-12-02
ES2848025T3 (es) 2021-08-05
MX2015002842A (es) 2015-08-12
CA2883703C (en) 2021-10-19
CN112451486A (zh) 2021-03-09
WO2014039533A2 (en) 2014-03-13
HK1212593A1 (en) 2016-06-17

Similar Documents

Publication Publication Date Title
US11291644B2 (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
JP6392209B2 (ja) 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
CN115087665A (zh) 用于靶向递送治疗剂的工程化血小板
Li et al. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma
TW200413000A (en) Intrinsic repair factor producing accelerator
US20100151006A1 (en) Cancer therapy sensitizer
KR20110132446A (ko) 키나아제 단백질 결합 억제제
JPWO2008120815A1 (ja) がん細胞および癌随伴線維芽細胞への標的化剤
JPWO2014069401A1 (ja) 肺疾患特異的治療剤
JP2015513543A (ja) 癌および他の状態を処置するためのナノ構造体
KR20170132152A (ko) 나노입자를 이용한 종양 치료 조성물 및 방법
Hou et al. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models
AU2018345652A1 (en) Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
TWI725947B (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
Xu et al. Targeted inhibition of STAT3 (Tyr705) by xanthatin alleviates osteoarthritis progression through the NF-κB signaling pathway
Tang et al. Cancer stem cells and combination therapies to eradicate them
JP4671962B2 (ja) デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤
Todd et al. LiF@ SiO2 nanocapsules for controlled lithium release and osteoarthritis treatment
CN114948959B (zh) 一种调控肿瘤乳酸代谢的纳米药物及其制备方法和应用
JPWO2005004914A1 (ja) ＮＦ−κＢデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法
Weber et al. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
HK1212593B (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
Sun et al. Bergenin and vitexin delivery platform using mouse lung fibroblasts-derived exosomes for bleomycin-induced pulmonary fibrosis therapy
EP4157457A1 (en) Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180118